仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Briakinumab （ABT-874） is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis